West Pharmaceutical (WST) Misses Q2 EPS by 5c; Adjusts FY11 Outlook
West Pharmaceutical Services, Inc. (NYSE: WST) reported Q2 EPS of $0.62, $0.05 worse than the analyst estimate of $0.67. Revenue for the quarter came in at $307.9 million versus the consensus estimate of $299.45 million.
West Pharmaceutical Services, Inc. sees FY2011 EPS of $2.30-$2.40, versus prior guidance of $2.30-$2.50 and the consensus of $2.38. West Pharmaceutical Services, Inc. sees FY2011 revenue of $1.17-$1.20 billion, versus prior guidance of $1.16-$1.19 billion and the consensus of $1.18 billion.
West Pharmaceutical Services, Inc. sees FY2011 EPS of $2.30-$2.40, versus prior guidance of $2.30-$2.50 and the consensus of $2.38. West Pharmaceutical Services, Inc. sees FY2011 revenue of $1.17-$1.20 billion, versus prior guidance of $1.16-$1.19 billion and the consensus of $1.18 billion.